Programme award

//images.ctfassets.net/tcii3zrq4kfu/bo0YC0LW4oWwuaCgmwKYm/b561734237357c6254296dd4b96e1ae7/Header-page-programe-award.jpg Header-page-programe-award

L’efficacité de Trulicity® est portée par les études AWARD, un large programme de développement clinique incluant :
10 études de phase III
1 étude de phase IV et plus de 16000 patients.

GLP-1 : Glucagon-Like Peptide-1.
1. Giorgino F, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2).
Diabetes Care. 2015;38(12):2241-9.
2. Nauck M, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care.2014;37(8):2149-58.
3. Dungan KM, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349-57.
4. H9X-MC-GBDX Clinical Study Report Body. A randomized, open-label, parallel-arm study comparing the effect of once-weekly dulaglutide with insulin glargine on glycemic control in patients with type 2 diabetes and moderate or severe chronic kidney disease (AWARD-7: assessment of weekly administration of LY2189265 in diabetes – 7. Mai 2017. Pages 64, 66, 67, 68, 72, 73, 180, 182, 221, 223, 228, 232, 240, 272, 273, 280, 284, 449, 452, 455, 456, 770, 1555, 1563, 1587.
5. Pozzilli P, et al. Placebo-controlled, randomized trial of the addition of once weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;1–8.

PP-DG-FR-0120 - 18/04/63787647/PM/005 – V2 Vbis – Novembre 2018 – ©Lilly. Tous droits de reproduction réservés.

Top